source
- Tortugas Neuroscience's obuprazine shows significant improvement in phase 2b schizophrenia trial in ChinaTortugas Neuroscience, a biotech founded by former Sage Therapeutics staff with $106 million in funding, reported positive data from a phase 2b study of its schizophrenia candidate obuprazine, lice…
- First Tracks reports positive early-stage results for celiac drug ANB033First Tracks Biotherapeutics announced that its experimental celiac disease drug ANB033 showed statistically significant improvement in a six‑week early‑stage trial compared with placebo. The trial…